Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 1.39B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 10.32M |
| Shares Out | 154.20M |
| EPS (ttm) | 0.06 |
| PE Ratio | 78.00 |
| Forward PE | 8.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 877,763 |
| Open | 4.57 |
| Previous Close | 4.55 |
| Day's Range | 4.55 - 4.71 |
| 52-Week Range | 1.24 - 4.79 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 4.80 (+2.35%) |
| Earnings Date | Nov 7, 2023 |
About AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price forecast is $4.8, which is an increase of 2.35% from the latest price.
News
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
BRIDGEWATER, N.J. & PORTO, Portugal--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal w...
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition of Icosapent ethyl...
Amneal Reports Third Quarter 2023 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2023. “We are pleased to...
Amneal to Participate at Upcoming Investor Conferences
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer,...
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended Se...
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia® and XGEVA® ...
Amneal to Report Third Quarter 2023 Results on November 7, 2023
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2023 Results on November 7, 2023.
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U....
Amneal Receives First Product Approval in China
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received its first product approval in China. Sevelamer carbonate was a...
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S....
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Fi...
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safet...
Amneal Reports Second Quarter 2023 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2023. “We are pleased to rai...
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such investors are advis...
Amneal to Report Second Quarter 2023 Results on August 4, 2023
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to...
US FDA declines to approve Amneal Pharma's Parkinson's drug
The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' drug for Parkinson's disease due to inadequate safety data on the treatment to help control symptoms in pati...
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the launch of its authorized generic for Xyrem®1 (Sodium Oxybate) oral solutio...
Amneal Receives U.S. FDA Complete Response Letter for IPX203
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug A...
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its third annual (2022) Environmental, Social and Governance (E...
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the 505(b)(2) New Drug Application (NDA) approval from the U.S. Food and Drug ...
Amneal to Participate at the 2023 Jefferies Healthcare Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Fi...
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referenc...
Amneal Reports First Quarter 2023 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023. “We are very pl...
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Fi...